← Alcon Research (ALC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alcon Research (ALC)
Ophthalmic Goods · market cap $31.9B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-10
Earnings
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Alcon Inc. (ALC) is a Swiss-American ophthalmic pharmaceutical and medical device company headquartered in Geneva with primary operations in Fort Worth, Texas. The company carries a $11.6B market cap at ~$67.14/share and fields a broad pipeline spanning glaucoma, allergic conjunctivitis, uveitis, AMD, dry eye, and surgical/cataract indications — most assets in Phase 2 or Phase 3. The nearest identifiable binary catalyst is a Phase 2 readout for AR-14034 SR implant (neovascular AMD) estimated May 2027.
The catalyst path
- 2026-11-10Earningsimp 5/10
- 2027-04-15 (est.)Phase 2 · AR-14034 SR implant lower doseimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Travoprost Vehicle | Phase 2 | Open-angle Glaucoma (OAG) |
| Olopatadine Hydrochloride Ophthalmic Solution, 0.2% | Phase 3 | Allergic Conjunctivitis |
| LME636 60 mg/mL ophthalmic solution | Phase 2 | Acute Anterior Uveitis |
| Anecortave acetate 30 mg | Phase 2 | AMD |
| AL-3789 Sterile Suspension | Phase 2 | Open-angle Glaucoma |
| AL-4943A ophthalmic solution | Phase 3 | Allergic Conjunctivitis |
| Ofloxacin otic solution | Phase 3 | Acute Otitis Media |
| Difluprednate 0.05% ophthalmic emulsion | Phase 3 | Endogenous Anterior Uveitis |
| Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution | Phase 3 | Glaucoma, Open-angle |
| Brinzolamide 1% ophthalmic suspension | Phase 3 | Open-Angle Glaucoma |
| Difluprednate ophthalmic emulsion, 0.05% | Phase 3 | Cataracts |
| Travoprost 0.004%/Timolol 0.5% | Phase 3 | Open-angle Glaucoma |
| Travoprost 0.004% with and without BAK | Phase 3 | Open-angle Glaucoma |
| Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension | Phase 3 | Cataract |
| Travoprost, Investigational | Phase 3 | Open-angle Glaucoma |
| Next Generation Ophthalmic Irrigating Solution (NGOIS) | Phase 3 | Cataract |
| Tobramycin 0.3%/Dexamethasone 0.05% | Phase 3 | Ocular Inflammation Associated With Blepharaconjunctivitis |
| AL-39324 ophthalmic suspension | Phase 2 | Age Related Macular Degeneration |
| Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension | Phase 3 | Open-Angle Glaucoma |
| Brinzolamide ophthalmic suspension, 1% | Phase 3 | Open-Angle Glaucoma |
Price & technical context
3-month
-8.2%
6-month
-15.3%
12-month
-14.2%
52-wk range
$62.02–$87.18
vs 50-day MA
-8.1%
vs 200-day MA
-12.8%
Realized vol
28.0%
Max drawdown
-38.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.